Manager, CMC Regulatory Affairs

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is Deramiocel (CAP-1002), our lead cell therapy in late-stage development for Duchenne muscular dystrophy. We are also harnessing our proprietary StealthX™ exosome platform to unlock new possibilities in targeted delivery and vaccinology. Every program reflects our commitment to pushing the boundaries of science and delivering life-changing treatments to patients and families who need them most.

The Manager, CMC Regulatory Affairs is responsible for executing Chemistry, Manufacturing, and Controls (CMC) regulatory activities across Capricor’s product lifecycle, with a primary focus on supporting the BLA pathway for Deramiocel and advancing other pipeline candidates from development through potential commercial approval and post-approval maintenance. This role supports the development and implementation of CMC regulatory strategy, ensures compliance with global regulatory requirements (including FDA, ICH, and EMA guidelines), and partners closely with cross-functional teams (e.g., CMC Development, Manufacturing, Quality Assurance, Clinical, and Regulatory) to enable timely submissions, successful interactions with health authorities, and achievement of company objectives in a dynamic biotech environment.